Tigenix (Tig - Euronext Bruxelles)

TiGenix is a biomedical company that focuses on innovative local treatments for damaged and osteoarthritic joints. Based in Leuven, Belgium, TiGenix was founded in 2000 by Professor Frank P. Luyten, rheumatologist and renowned scientist and Gil Beyen MBA, bioengineer and CEO of the company since its inception. 

TiGenix is built on technologies developed at the Catholic University of Leuven and the University of Ghent. The company’s scientific background and expertise has concentrated on the developmental biology of cartilage, bone and other connective tissues. The insights TiGenix’ scientific founders gained into the biology of cartilage have led to the development of a technology platform focused on finding solutions for damaged and diseased cartilage. 

The company is exploiting the power of regenerative medicine to develop durable treatments, validated through controlled, prospective, multi-centre clinical trials. Western societies are characterized by ageing populations that place an increasing emphasis on a high quality of life and life-long mobility. As such, musculoskeletal problems represent a large and growing unmet medical need. Current therapies do not provide satisfying, long-term durable repair. TiGenix therefore believes that there is a need for more long-lasting and effective treatments for cartilage damage. The company is developing a portfolio of products which address specific musculoskeletal problems. The lead indication is cartilage damage, which is a debilitating affliction affecting the mobility and functioning of patients.